Skip to main content
S&P 5007,720.39-0.30%DOW52,342.56-0.25%NASDAQ26,184.72-1.38%BTC$77,565.00-3.36%ETH$2,242.34-3.63%GOLD$3,989.90-1.03%OIL$104.17+2.13%
Smart Investors Daily
SID Premium
TS

NASDAQ · TSHA

Taysha Gene Therapies, Inc.

Healthcare · Biotechnology

$4.22

Down-$0.01 (-0.24%)

Updated Oct 30, 2026, 10:21 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.51B
P/E ratio
-20.4
Dividend yield
0.00%
52-week range
$3.46 – $7.30
Volume
2.06M
Avg. volume
6.31M

Price performance · TSHA

TSHA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

TSHA closed at $4.22 after 21 trading sessions, down 10.97% for the selected period.

Last close
$4.22
Period change
-10.97%
Period low
$3.51
Period high
$4.74
Daily close
View OHLC price history
TSHA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$4.225$4.47$4.14$4.222.06M
Oct 28, 2026$4.24$4.28$4.12$4.233.4M
Oct 27, 2026$4.03$4.28$3.97$4.252.82M
Oct 26, 2026$3.98$4.09$3.95$4.011.82M
Oct 23, 2026$3.95$3.98$3.755$3.962.59M
Oct 22, 2026$4.07$4.175$3.935$4.0053.11M
Oct 21, 2026$4.15$4.265$4.05$4.123.51M
Oct 20, 2026$3.95$4.20$3.89$4.1110.93M
Oct 19, 2026$3.66$3.965$3.65$3.945.82M
Oct 16, 2026$3.73$3.745$3.60$3.622.75M
Oct 15, 2026$3.53$3.79$3.50$3.734.69M
Oct 14, 2026$3.51$3.715$3.455$3.514.34M
Oct 13, 2026$4.09$4.13$3.55$3.586.12M
Oct 12, 2026$4.46$4.56$4.125$4.144.21M
Oct 9, 2026$4.42$4.565$4.36$4.495.38M
Oct 8, 2026$4.37$4.455$4.325$4.433.91M
Oct 7, 2026$4.33$4.46$4.26$4.433.91M
Oct 6, 2026$4.51$4.57$4.26$4.394.84M
Oct 5, 2026$4.64$4.64$4.37$4.494.98M
Oct 2, 2026$4.80$4.86$4.63$4.632.99M
Oct 1, 2026$4.86$4.935$4.73$4.743.85M

Latest TSHA news

The latest Smart Investors Daily articles mentioning TSHA.

Stock researchCompany · Overview

TSHA research

Overview

Company profile and research snapshot.

Company profile

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.83
Implied upside
—
Analysts
—
TSHA recent ratings
DateFirmRatingTarget
Sep 17, 2026Wolfe ResearchOutperform—
Jul 21, 2026Goldman SachsBuy—
Jul 2, 2026CitizensMarket Outperform—
Jun 30, 2026BairdOutperform—
Jun 30, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?

Taysha Gene Therapies reported phase 1/2 REVEAL data in Rett syndrome, where all 10 participants receiving a single intrathecal TSHA-102 dose gained or regained at least one developmental milestone and no treatment-related serious adverse events were observed. These findings support the therapy's potential to modify the disease course. The combination of consistent functional gains across all treated patients and a clean treatment-related serious safety profile highlights how TSHA-102 could...

Yahoo · Oct 9, 2026

Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value

Taysha Gene Therapies has delivered a 90.1% gain over the past three years, which puts fresh attention on whether that kind of move is backed up by the value on its balance sheet. With the share price at US$4.43 at the last close, the live question is how comfortably that level sits against the company’s book value compared with the wider industry. The 90.1% rise over three years raises the stakes for investors who want to know if the current valuation is still supported by what Taysha Gene...

Yahoo · Oct 9, 2026

Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?

Taysha Gene Therapies (TSHA) has drawn fresh attention after a period of pressure on the share price, with the stock roughly flat over the past day but lower over the past month and the past three months. Short term momentum for Taysha Gene Therapies has clearly cooled, with the 7 day share price return down 6.54% and the 30 day move down 19.16% at a last close of US$4.43. Over a slightly longer stretch, the 90 day share price return is down 30.13% and the year to date share price return is...

Yahoo · Oct 2, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees restricted stock units (RSUs) representing 384,000 shares of the Company’s common stoc

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By